Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence.

ABSTRACT:

Background

The ERBB2 oncogene hypothesis is challenged in hepatocellular carcinoma (HCC) with the conflicting evidences of human epidermal growth factor receptor 2 (HER2) overexpression. HER2 could be a new target as a treatment option for HCC as well as tumor recurrence after surgery. HER2 in HCC biology needs further explorations.

Methods

Clinical and mRNA data of HCC patients were obtained from TCGA HCC cohort, GSE89377 and GSE115018. Western Blotting and immunohistochemistry were employed to test expression of HER2, E-cadherin, and Vimentin. In HepG2, JM1, HER2-transfected McA cells, and TGF-β cocultured JM1 cells, HCC biology, including cell survival, proliferation, and epithelial-to-mesenchymal transition (EMT) phenotypes were evaluated.

Results

ERBB2 mRNA ampli

SUBMITTER: Shi JH 

PROVIDER: S-EPMC6434216 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature